This is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
The Parker Institute
Frederiksberg, Capital Region, Denmark
Change in collagen II degradation fragment α-C2M
Blood sampling
Time frame: Week 0 to 52
Change in collagen II degradation fragment β-C2M
Blood sampling
Time frame: Week 0 to 52
Change in non-coding RNA type snoRNAs U38 and U48
Blood sampling
Time frame: Week 0 to 52
Change in miRNA-454
Blood sampling
Time frame: Week 0 to 52
Change in miRNA let-7e
Blood sampling
Time frame: Week 0 to 52
Change in Nesfatin-1
Blood sampling
Time frame: Week 0 to 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.